Clinical Trials Flood India But Infrastructure Woes Stifle Cancer Trials
This article was originally published in PharmAsia News
Executive Summary
AHMEDABAD, India - As the number of clinical trials grow steadily in India to reach over $1 billion in turnover, a peculiar "problem of plenty" faces clinical trials for specialized cancer drugs